Fig-1 (Doxo 10mg 50mg Inj Mylan Figure 02)
Doxorubicin Hydrochloride
Product Images NDC 67457-478
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 67457-478). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Fig-2 (Doxo 10mg 50mg Inj Mylan Figure 03)
This text seems to be a list of different clinical trials or study names. It does not offer any further details or context. Therefore, it can't provide a useful description.*
Structure (Image 01)
The text appears to be indicating chemical information of a substance. It provides the chemical formula C_HNO and the abbreviation for Hydrochloride (HCI), which suggests it may be a salt form. Moreover, it indicates the molecular weight (MW) of the substance as 570.00 g/mol. It is possible that this text is part of a larger chemical description, but on its own, it only provides basic information.*
10 mg Carton (Image 02)
Doxorubicin Hydrochloride is a cytotoxic drug available in a 10 mg dose per vial. It must be reconstituted with 5 mL 0.9% Sodium Chloride Injection and should not be prescribed without thorough knowledge of dose, indications, and toxicity. After being reconstituted, the solution is stable for 7 days at room temperature and 15 days under refrigeration. Doxorubicin Hydrochloride is used for intravenous use only and must be protected from light. The packaging insert provides complete prescribing information, including dilution recommendations before administration.*
50 mg Carton (Image 03)
This is a description of a medication labeled as "DOXOrubicin Hydrochloride for Injection," which is a cytotoxic agent that should not be prescribed without a thorough understanding of dose, indications, and toxicity associated with it. The medication is packaged in a vial with a sterile powder that contains doxorubicin HCI, USP 50 mg and lactose monohydrate 250 mg as an inactive ingredient. The vial should be stored at room temperature, 20° to 25°C (68° to 77°F), and should be protected from light until use. The medication is reconstituted using 25 mL 0.9% Sodium Chloride Injection, USP and is for intravenous use only. The solution is stable for 7 days at room temperature and 15 days under refrigeration after reconstitution. The packaging comes with a package insert with complete prescribing information that includes usual dosage instructions. Extravasation of the medication during administration can cause severe cellulitis, vesication, and tissue necrosis. There is additional information on the packaging about the manufacturer and manufacturing location.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
